Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 74 Hodgkin Disease 56 Lymphoma 22 Sarcoma 13 Neoplasm Metastasis 11 Leiomyosarcoma 8 Uveal Melanoma 7 Neoplasms 7 Skin Neoplasms 6 Neuroblastoma 4 Sarcoma, Synovial 3 Recurrence 3 Solitary Fibrous Tumors 2 Sarcoma, Alveolar Soft Part 2 Hematologic Diseases 2 HIV Infections 2 Thyroid Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Skin Diseases 1 Sarcoma, Ewing 1 Sarcoma, Clear Cell 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Parathyroid Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neurofibrosarcoma 1 Neuroendocrine Tumors 1 Melanoma, Cutaneous Malignant 1 Melanoma Neoplasms 1

Interventions

tislelizumab 2 Oxaliplatin 2 tremelimumab 1 olaparib 1 durvalumab 1 apatinib 1 Tegafur 1 Immunotherapy, Adoptive 1 Dacarbazine 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Immunotherapy × Dacarbazine × Clear all

NCT04225390 2026-02-10

PROMIT

University of Erlangen-Nürnberg Medical School

Phase 2 Completed

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡